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LETTER
Abnormal retinal thickening is
a common feature among
patients with ARSACS-related
phenotypes
Autosomal-recessive spastic ataxia of
Charlevoix-Saguenay (ARSACS) was first
described among French Canadian patients
from Québec presenting with a stereotyp-
ical triad of early-onset cerebellar ataxia,
spastic paraplegia and peripheral neur-
opathy. Two recurring pathogenic muta-
tions in the SACS gene were subsequently
identified in these families in keeping with a
mutational founder event in a geographic-
ally isolated population.1 However,
ARSACS is being increasingly recognised
worldwide as an important cause of inher-
ited ataxia.2 Interestingly, non-Québec
patients can show strikingly variable fea-
tures marked by a lack of spasticity, cogni-
tive impairment and a delayed age of
onset.2 Given the heterogeneous clinical
picture that can be associated with SACS
mutations, the identification of ancillary
features linked with these genetic defects
could prove particularly useful in prioritis-
ing the most appropriate lines of investiga-
tions when confronted with a suspected
case of ARSACS. Although prominent
retinal hypermyelination is thought to be a
characteristic manifestation of classical
ARSACS among Québec patients, this oph-
thalmological finding has only been
described infrequently in patients from
Europe, Asia and the Middle East.2 A
recent case report has even further argued
that retinal ‘hypermyelination’ in ARSACS
is a pathologically misleading term that
should be abandoned in favour of retinal
nerve fibre layer (RNFL) hypertrophy.3
To more accurately define the nature of
the retinal findings in ARSACS and its pos-
sible practical relevance as a screening tool
in routine clinical practice, we carried out a
comprehensive neuro-ophthalmological
examination of five patients from the North
of England with molecularly confirmed
ARSACS (table 1).4 5 Topographic analysis
of the optic disc was performed with the
Spectralis optical coherence tomography
(OCT) platform (Heidelberg Engineering,
Heidelberg, Germany).
No patient had evidence of retinal
hypermyelination. Retinal striations were
observed around the optic discs in four
patients (A, B, C and D) and OCT mea-
surements showed significant generalised
peripapillary RNFL thickening (see online
supplementary figures S1–S4). Patient E
had no fundus abnormalities, and the
peripapillary RNFL thickness was within
the normal range for healthy controls (see
online supplementary figure S5).
Our case series has provided convincing
evidence that abnormal retinal thickening
is a common, although not universal,
feature among patients with
ARSACS-related phenotypes secondary to
pathogenic SACS mutations. Significant
peripapillary RNFL thickening has also
been previously reported in eight patients
harbouring confirmed pathogenic SACS
mutations with different OCT imaging
platforms to the one used in our study.6–8
Classical myelinated retinal nerve fibres
were not observed, and the current body
of evidence, at least among non-Québec
patients, suggests that retinal ‘hypermyeli-
nation’ has been used inappropriately to
describe the striated appearance of a
thickened RNFL around the optic discs.
The pathophysiological basis for this
observation remains to be determined, but
it is rather revealing that the sacsin
protein localises to mitochondria. In a
transgenic knock-out mouse model, deple-
tion of the sacsin protein resulted in dis-
ruption of mitochondrial axonal transport
and cerebellar neurones with aberrant
dendritic morphologies.9 Although specu-
lative, RNFL thickening in ARSACS could
therefore be related to axoplasmic stasis
within the long axons of the retinal gan-
glion cells as they converge to form the
optic nerve in the anatomically con-
strained region of the lamina cribosa.
The investigation of a large multicentre
cohort of patients with ARSACS will be
needed to determine whether the degree of
RNFL thickening correlates with disease
severity and progression or whether there
are any specific genotype–OCTcorrelations.
The molecular genetic basis of inherited
ataxia and spastic paraplegia syndromes is
highly heterogeneous—a situation that
poses a number of diagnostic challenges in
neurology clinics. In Friedreich’s ataxia,
which is the most common form of auto-
somal recessive ataxia, variable reduction in
RNFL thickness has been reported among
visually asymptomatic patients.10 In a recent
OCT study, we found a normal RNFL
profile among patients harbouring SPG4
mutations, which account for ∼40% of all
autosomal-dominant cases of hereditary
spastic paraplegia.11 A dilated fundus exam-
ination and OCT imaging should therefore
be considered in patients with unexplained
multisystem neurological disease. When
present, retinal striations and RNFL thick-
ening raise the distinct possibility of
Table 1 Clinical features and retinal nerve fibre layer measurements in patients with pathogenic SACS mutations
Patient
Age
(years) Sex
Onset
(years) Clinical features SACS mutations
Average RNFL
Thickness
OD (μm) OS (μm)
A 48 F 26 Gait ataxia, dysarthria, spastic paraplegia and
peripheral neuropathy
c.2076delG (p.Thr692ThrfsX713);
c.3965_3966delAC (p.Gly1322ValfsX1343)
174 175
B 45 M 19 Gait ataxia, dysarthria, spastic paraplegia and
peripheral neuropathy
162 140
C 43 M Late-teens Gait ataxia, dysarthria, proximal myopathy and
peripheral neuropathy
c.13048G>T (p.Glu4350X); 0.7Mb deletion
(13q12.12)
138 122
D 46 M Mid-teens Gait ataxia, dysarthria, proximal myopathy and
peripheral neuropathy
152 169
E 69 M Late-teens Gait ataxia, spastic paraplegia and peripheral
neuropathy
c.1580C>G (p.Ser527X); c.6781C>A (p.
Leu2261Ile)
111 86
Patients A and B, and patients C and D, are two pairs of siblings. The molecular genetic characterisation of these four patients with next-generation whole exome sequencing has been
previously reported.4 5 All the patients presented with progressive gait ataxia and they were severely disabled, requiring the use of a wheelchair for ambulation. Four patients (A, B, C
and D) had significant peripapillary RNFL thickening outside the normal range for healthy controls (mean average thickness=100.3 μm, SD=1.8 μm). No patient had a significant
refractive error that could be a confounding variable in the analysis of peripapillary RNFL thickness.
OD, right eye; OS, left eye; RNFL, retinal nerve fibre layer.
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